Aquestive Therapeutics Stock Profit Margin
| AQST Stock | USD 4.57 0.26 5.38% |
Aquestive Therapeutics fundamentals help investors to digest information that contributes to Aquestive Therapeutics' financial success or failures. It also enables traders to predict the movement of Aquestive Stock. The fundamental analysis module provides a way to measure Aquestive Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aquestive Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | (0.16) | (0.16) |
Aquestive | Profit Margin |
Aquestive Therapeutics Company Profit Margin Analysis
Aquestive Therapeutics' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Aquestive Therapeutics Profit Margin | (0.60) % |
Most of Aquestive Therapeutics' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aquestive Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Aquestive Profit Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Aquestive Therapeutics is extremely important. It helps to project a fair market value of Aquestive Stock properly, considering its historical fundamentals such as Profit Margin. Since Aquestive Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aquestive Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aquestive Therapeutics' interrelated accounts and indicators.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Aquestive Pretax Profit Margin
Pretax Profit Margin |
|
Based on the latest financial disclosure, Aquestive Therapeutics has a Profit Margin of -0.5975%. This is 94.67% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The profit margin for all United States stocks is 52.95% lower than that of the firm.
Aquestive Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aquestive Therapeutics' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aquestive Therapeutics could also be used in its relative valuation, which is a method of valuing Aquestive Therapeutics by comparing valuation metrics of similar companies.Aquestive Therapeutics is currently under evaluation in profit margin category among its peers.
Aquestive Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Aquestive Therapeutics from analyzing Aquestive Therapeutics' financial statements. These drivers represent accounts that assess Aquestive Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Aquestive Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 147.6M | 180.0M | 148.1M | 44.0M | 123.7M | 141.9M | |
| Enterprise Value | 158.6M | 188.7M | 176.5M | 72.8M | 133.2M | 155.3M |
Aquestive Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Aquestive Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Aquestive Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Aquestive Fundamentals
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.60) % | ||||
| Operating Margin | (0.61) % | ||||
| Current Valuation | 399.37 M | ||||
| Shares Outstanding | 91.18 M | ||||
| Shares Owned By Insiders | 5.00 % | ||||
| Shares Owned By Institutions | 51.64 % | ||||
| Number Of Shares Shorted | 10.14 M | ||||
| Price To Earning | (1.90) X | ||||
| Price To Sales | 7.07 X | ||||
| Revenue | 50.58 M | ||||
| Gross Profit | 28.29 M | ||||
| EBITDA | 1.18 M | ||||
| Net Income | (7.87 M) | ||||
| Cash And Equivalents | 17.7 M | ||||
| Cash Per Share | 0.33 X | ||||
| Total Debt | 33.32 M | ||||
| Debt To Equity | 468.20 % | ||||
| Current Ratio | 1.47 X | ||||
| Book Value Per Share | (0.50) X | ||||
| Cash Flow From Operations | (6.38 M) | ||||
| Short Ratio | 7.97 X | ||||
| Earnings Per Share | (0.45) X | ||||
| Target Price | 10.06 | ||||
| Number Of Employees | 135 | ||||
| Beta | 2.82 | ||||
| Market Capitalization | 416.68 M | ||||
| Total Asset | 57.42 M | ||||
| Retained Earnings | (319.08 M) | ||||
| Working Capital | 22.66 M | ||||
| Current Asset | 38.38 M | ||||
| Current Liabilities | 17.95 M | ||||
| Net Asset | 57.42 M |
About Aquestive Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aquestive Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aquestive Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aquestive Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aquestive Stock Analysis
When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.